Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to provide a framework for regulating therapeutic goods, including medicines, medical devices, and blood products, within Australia. The Act was introduced to address the need for a comprehensive legislative structure that ensures the safety, quality, and efficacy of therapeutic goods available to the public. This legislation is enacted by the Australian Parliament and its overarching policy objective is to protect public health by ensuring that therapeutic goods are of acceptable quality and that their use does not pose unacceptable risks. This gazette, issued by David Rowbury as the delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, serves to notify the public of the revocation of specific manufacturing licences for therapeutic goods, as requested by the manufacturers themselves. Such revocations are a part of the ongoing regulatory process to maintain compliance and uphold the standards set forth by the Act.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the manufacture, supply, or distribution of therapeutic goods within Australia. This includes individuals, businesses, and other entities that produce, package, label, import, or otherwise engage in the supply chain of therapeutic goods, which encompasses medicines, medical devices, and other health-related products. The Act establishes a regulatory framework to ensure that these goods meet safety, quality, and efficacy standards. The Act’s jurisdiction covers the entire Commonwealth of Australia, ensuring a uniform regulatory approach across all states and territories. However, certain exclusions and exemptions apply, such as to goods for personal use, research, or products used in clinical trials under specific conditions. The Act can extend or restrict its application through subordinate instruments, such as regulations or codes, which provide further detail and operational guidelines for compliance with the Act. These instruments help to clarify the scope of the Act and ensure consistent application of its provisions.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) empowers the Secretary of the Department of Health, Therapeutic Goods Administration (TGA) to revoke a Licence to Manufacture Therapeutic Goods under section 41(1)(d). This specific notification under section 41 revokes the Licence held by BMDI Cord Blood Bank, Johnson & Johnson Medical Pty Ltd, Jurlique International Pty Ltd, Antaria Ltd, and Sylvan Pharmaceuticals Pty Ltd. The revocation of these licences was at the request of the manufacturers themselves, indicating a voluntary withdrawal from the manufacturing authorisation process. The Act imposes several obligations on entities holding a Licence to Manufacture Therapeutic Goods, which include adhering to stringent quality standards, maintaining proper records, and ensuring that manufacturing processes meet the regulatory requirements set forth by the TGA. These obligations are designed to safeguard public health by ensuring that therapeutic goods are safe, of high quality, and effective for their intended use. The manufacturers, as holders of these licences, were required to comply with these obligations until their licences were revoked. Failure to comply with the provisions of the Act can lead to serious consequences. Under section 86(1) of the Act, an individual or entity can be subject to criminal penalties, including fines of up to $22,200 for a corporation and imprisonment for up to two years. Additionally, section 87(1) allows for civil penalties, which can include substantial fines and, in serious cases, court-ordered cessation of manufacturing activities. These penalties underscore the importance of adhering to the legislative requirements and maintaining the integrity of the therapeutic goods manufacturing process.